Randomized trial of cyclophosphamide, methotrexate, and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive estrogen and/or progesterone receptor-positive breast cancer: a report of the National Cancer Institute of Canada Clinical Trials Group. Breast Cancer Site Group.

摘要: PURPOSE AND METHODSBy the mid 1980s, tamoxifen alone was considered standard adjuvant therapy for postmenopausal women with node-positive, estrogen receptor (ER)- or progesterone (PgR)-positive breast cancer. From 1984 through 1990, 705 eligible ER- PgR-positive cancer were randomized to a National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) study that compared 30 mg by mouth daily 2 years (TAM) versus TAM plus chemotherapy all-intravenous cyclophosphamide 600 mg/m2, methotrexate 40 and fluorouracil mg/m2 given every 21 days eight cycles (CMF).RESULTSThere no significant differences in overall survival, recurrence-free locoregional distant survival between two treatment arms. However, there significantly greater severe toxicity, which included leukopenia (P < .0001), nausea vomiting thromboembolic events ...